Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) Net Income towards Common Stockholders (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Net Income towards Common Stockholders for 6 consecutive years, with -$6.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 989.66% year-over-year to -$6.7 million, compared with a TTM value of -$56.7 million through Dec 2025, down 1.12%, and an annual FY2025 reading of -$56.7 million, down 1.12% over the prior year.
  • Net Income towards Common Stockholders was -$6.7 million for Q4 2025 at Treace Medical Concepts, up from -$16.4 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$619000.0 in Q4 2024 and bottomed at -$21.3 million in Q2 2024.
  • Average Net Income towards Common Stockholders over 5 years is -$11.3 million, with a median of -$12.2 million recorded in 2022.
  • The sharpest move saw Net Income towards Common Stockholders surged 90.29% in 2024, then crashed 989.66% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$6.6 million in 2021, then skyrocketed by 33.34% to -$4.4 million in 2022, then plummeted by 44.54% to -$6.4 million in 2023, then soared by 90.29% to -$619000.0 in 2024, then plummeted by 989.66% to -$6.7 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for TMCI at -$6.7 million in Q4 2025, -$16.4 million in Q3 2025, and -$17.5 million in Q2 2025.